We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CCCC market cap is 423.95M. The company's latest EPS is USD -1.9314 and P/E is -3.19.
| Quarter End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 7.65M | 13.83M | 6.75M | 2.85M | 3.76M |
| Operating Income | -31.37M | -27.38M | -32.49M | -38.29M | -36.23M |
| Net Income | -31.62M | -27.41M | -31.96M | -37.19M | -34.78M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 21.38M | 33.2M | 45.79M | 31.1M | 20.76M |
| Operating Income | -35.45M | -60.45M | -82.13M | -129.53M | -139.03M |
| Net Income | -42.57M | -66.34M | -83.89M | -128.18M | -132.49M |
| Quarter End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 515.49M | 492.48M | 461.44M | 430.84M | 396.04M |
| Total Liabilities | 150.96M | 147.88M | 143.26M | 141.61M | 133.57M |
| Total Equity | 364.53M | 344.59M | 318.18M | 289.23M | 262.47M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 118.26M | 400.14M | 506.77M | 430.84M | 376.45M |
| Total Liabilities | 119.23M | 119.35M | 117.16M | 141.61M | 130.34M |
| Total Equity | -111.96M | 280.79M | 389.61M | 289.23M | 246.11M |
| Quarter End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -26.6M | -48.79M | -76.81M | -105.94M | -33.13M |
| Investing | -4M | 29.22M | 49.14M | 58.42M | 53.53M |
| Financing | 480k | 739k | 1.1M | 1.15M | -684k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 55.61M | -67.25M | -86.97M | -105.94M | -106.84M |
| Investing | -1.62M | -190.51M | -189.34M | 58.42M | 158.35M |
| Financing | 244k | 348.93M | 171.4M | 1.15M | 45.49M |
| Market Cap | 423.95M |
| Price to Earnings Ratio | -3.19 |
| Price to Sales Ratio | 20.39 |
| Price to Cash Ratio | 3.34 |
| Price to Book Ratio | 1.72 |
| Dividend Yield | - |
| Shares Outstanding | 68.6M |
| Average Volume (1 week) | 1.17M |
| Average Volume (1 Month) | 1.28M |
| 52 Week Change | 103.29% |
| 52 Week High | 11.88 |
| 52 Week Low | 1.06 |
| Spread (Intraday) | 0.14 (2.21%) |
| Company Name | C4 Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.c4therapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
